Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

Czajka-Francuz P. et al, (2026), Br J Cancer

The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome.

Boucher AC. et al, (2026), Leukemia

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Gibson V. et al, (2026), Nat Commun, 17

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Sallman DA. et al, (2026), J Clin Oncol

Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.

Jackson A. et al, (2026), Lancet Reg Health Eur, 66

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Rampotas A. et al, (2026), Sci Transl Med, 18

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Pemmaraju N. et al, (2026), Blood

Engineering and improving anti-CTLA-4 checkpoint inhibitors.

Galvez-Cancino F. et al, (2026), Clin Cancer Res

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Schmid P. et al, (2026), Nat Cancer

Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023).

Perletta V. et al, (2026), ESMO Real World Data Digit Oncol, 12

The fetal specific gene LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia.

Ling RE. et al, (2026), Blood

Human haematopoietic stem cells remember inflammatory stress.

Zeng AGX. et al, (2026), Nature

Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Schmid P. et al, (2026), Clin Cancer Res

Initial leukemic epigenomic state determines hypomethylating agent response.

Gopal A. et al, (2026), Nat Commun

Beyond data and technology: the need for new thinking to enable the era of precision prevention.

Tsakiroglou M. et al, (2026), BMC Med

Load More

1
2
3
4
5
6
7
...
»